pI: 7.4147 |
Length (AA): 320 |
MW (Da): 34160 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 4 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
24 | 310 | 4dll (A) | 29 | 313 | 35.00 | 0 | 1 | 1.41507 | -0.98 |
25 | 306 | 3ws7 (A) | 0 | 280 | 42.00 | 0.000000037 | 1 | 1.47655 | -1.07 |
27 | 311 | 3doj (A) | 1 | 285 | 31.00 | 0.000000000006 | 1 | 1.39593 | -1.17 |
28 | 319 | 2cvz (A) | 3 | 289 | 28.00 | 0.0000043 | 1 | 1.2668 | -0.16 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | VEG Tachyzoite, ME49 Tachyzoite. | Gregory |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | ME49 Bradyzoite. | Sibley/Greg |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | ME49 merozoite. | Hehl AB |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 0-20% percentile | ME49 Oocyst. | Fritz HM |
Gregory | ToxoDB |
Sibley/Greg | ToxoDB |
Hehl AB | Asexual expansion of Toxoplasma gondii merozoites is distinct from tachyzoites and entails expression of non-overlapping gene families to attach, invade, and replicate within feline enterocytes. |
Fritz HM | Transcriptomic analysis of toxoplasma development reveals many novel functions and structures specific to sporozoites and oocysts. |
Ortholog group members (OG5_126809)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT4G29120 | 6-phosphogluconate dehydrogenase family protein |
Arabidopsis thaliana | AT3G25530 | gamma-hydroxybutyrate dehydrogenase |
Arabidopsis thaliana | AT4G20930 | probable 3-hydroxyisobutyrate dehydrogenase |
Arabidopsis thaliana | AT1G17650 | glyoxylate reductase 2 |
Candida albicans | CaO19.5565 | match to NAD binding domain of 6-phosphogluconate dehydrogenase (pentose-phosphate shunt pathway) |
Candida albicans | CaO19.13011 | match to NAD binding domain of 6-phosphogluconate dehydrogenase (pentose-phosphate shunt pathway) |
Caenorhabditis elegans | CELE_B0250.5 | Protein B0250.5 |
Dictyostelium discoideum | DDB_G0292566 | 3-hydroxyisobutyrate dehydrogenase |
Drosophila melanogaster | Dmel_CG15093 | CG15093 gene product from transcript CG15093-RB |
Drosophila melanogaster | Dmel_CG4747 | CG4747 gene product from transcript CG4747-RB |
Escherichia coli | b3125 | tartronate semialdehyde reductase |
Escherichia coli | b3882 | gamma-hydroxybutyrate dehydrogenase, NADH-dependent |
Escherichia coli | b0509 | tartronate semialdehyde reductase, NADH-dependent |
Escherichia coli | b2736 | putative dehydrogenase |
Homo sapiens | ENSG00000106049 | 3-hydroxyisobutyrate dehydrogenase |
Homo sapiens | ENSG00000140632 | glyoxylate reductase 1 homolog (Arabidopsis) |
Leishmania braziliensis | LbrM.30.0180 | 2-hydroxy-3-oxopropionate reductase, putative |
Leishmania donovani | LdBPK_300170.1 | 2-hydroxy-3-oxopropionate reductase, putative |
Leishmania infantum | LinJ.30.0170 | 2-hydroxy-3-oxopropionate reductase, putative |
Leishmania major | LmjF.30.0180 | 2-hydroxy-3-oxopropionate reductase, putative |
Leishmania mexicana | LmxM.29.0180 | 2-hydroxy-3-oxopropionate reductase, putative |
Mus musculus | ENSMUSG00000022536 | glyoxylate reductase 1 homolog (Arabidopsis) |
Mus musculus | ENSMUSG00000029776 | 3-hydroxyisobutyrate dehydrogenase |
Mycobacterium tuberculosis | Rv0751c | Probable 3-hydroxyisobutyrate dehydrogenase MmsB (hibadh) |
Mycobacterium tuberculosis | Rv0770 | Probable dehydrogenase/reductase |
Mycobacterium ulcerans | MUL_0835 | 3-hydroxyisobutyrate dehydrogenase |
Neospora caninum | NCLIV_034890 | 3-hydroxyisobutyrate dehydrogenase, putative |
Neospora caninum | NCLIV_024500 | NAD binding domain of 6-phosphogluconate dehydrogenase, putative |
Oryza sativa | 4329690 | Os02g0562700 |
Oryza sativa | 9270569 | Os02g0248100 |
Oryza sativa | 4326545 | Os01g0742300 |
Oryza sativa | 4326312 | Os01g0574600 |
Oryza sativa | 9268115 | Os06g0677400 |
Schmidtea mediterranea | mk4.006913.00 | 3-hydroxyisobutyrate dehydrogenase, mitochondrial |
Schmidtea mediterranea | mk4.064011.04 | |
Trypanosoma brucei gambiense | Tbg972.6.1240 | 2-hydroxy-3-oxopropionate reductase, putative |
Trypanosoma brucei | Tb927.6.1570 | 2-hydroxy-3-oxopropionate reductase, putative |
Trypanosoma congolense | TcIL3000_0_01600 | NAD binding domain of 6-phosphogluconate dehydrogenase/NAD-binding of NADP-dependent 3-hydroxyisobutyrate dehydrogenase, putativ |
Trypanosoma congolense | TcIL3000_0_16560 | 2-hydroxy-3-oxopropionate reductase, putative |
Trypanosoma congolense | TcIL3000_6_1070 | 2-hydroxy-3-oxopropionate reductase, putative |
Trypanosoma cruzi | TcCLB.505807.180 | 2-hydroxy-3-oxopropionate reductase, putative |
Trypanosoma cruzi | TcCLB.507017.40 | 2-hydroxy-3-oxopropionate reductase, putative |
Toxoplasma gondii | TGME49_263430 | 3-hydroxyisobutyrate dehydrogenase |
Toxoplasma gondii | TGME49_272410 | phosphogluconate dehydrogenase (decarboxylating), NAD binding domain-containing protein |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
mtu765 | Mycobacterium tuberculosis | non-essential | nmpdr |
mtu785 | Mycobacterium tuberculosis | non-essential | nmpdr |
Tb927.6.1570 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb927.6.1570 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb927.6.1570 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.6.1570 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
b0509 | Escherichia coli | non-essential | goodall |
b2736 | Escherichia coli | non-essential | goodall |
b3125 | Escherichia coli | non-essential | goodall |
b3882 | Escherichia coli | non-essential | goodall |
TGME49_272410 | Toxoplasma gondii | Probably non-essential | sidik |
TGME49_263430 this record | Toxoplasma gondii | Probably non-essential | sidik |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.3